Citigroup’s Palvella Therapeutics PVLA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $312K | Buy |
2,504
+500
| +25% | +$52.2K | ﹤0.01% | 3789 |
|
|
2025
Q4 | $210K | Buy |
2,004
+1,728
| +626% | +$147K | ﹤0.01% | 3984 |
|
|
2025
Q3 | $17.3K | Sell |
276
-2,150
| -89% | -$95.9K | ﹤0.01% | 4865 |
|
|
2025
Q2 | $54.7K | Buy |
2,426
+180
| +8% | +$4.22K | ﹤0.01% | 4710 |
|
|
2025
Q1 | $62.9K | Buy |
2,246
+1,138
| +103% | +$21.9K | ﹤0.01% | 4813 |
|
|
2024
Q4 | $13.3K | Hold |
1,108
| – | – | ﹤0.01% | 5330 |
|
|
2024
Q3 | $18.5K | Hold |
1,108
| – | – | ﹤0.01% | 5203 |
|
|
2024
Q2 | $10.9K | Buy |
1,108
+1
| +0.1% | +$11 | ﹤0.01% | 5120 |
|
|
2024
Q1 | $16.2K | Hold |
1,107
| – | – | ﹤0.01% | 5092 |
|
|
2023
Q4 | $16.1K | Hold |
1,107
| – | – | ﹤0.01% | 5057 |
|
|
2023
Q3 | $26.4K | Hold |
1,107
| – | – | ﹤0.01% | 4315 |
|
|
2023
Q2 | $14.7K | Hold |
1,107
| – | – | ﹤0.01% | 5014 |
|
|
2023
Q1 | $86.5K | Sell |
1,107
-1
| -0.1% | -$116 | ﹤0.01% | 4078 |
|
|
2022
Q4 | $92.2K | Sell |
1,108
-132
| -11% | -$10.6K | ﹤0.01% | 4058 |
|
|
2022
Q3 | $114K | Sell |
1,240
-4,311
| -78% | -$556K | ﹤0.01% | 4025 |
|
|
2022
Q2 | $830K | Sell |
5,551
-424
| -7% | -$77.4K | ﹤0.01% | 2823 |
|
|
2022
Q1 | $1.45M | Sell |
5,975
-181
| -3% | -$47.6K | ﹤0.01% | 2623 |
|
|
2021
Q4 | $1.86M | Buy |
6,156
+233
| +4% | +$74.6K | ﹤0.01% | 2686 |
|
|
2021
Q3 | $2.45M | Buy |
5,923
+756
| +15% | +$263K | ﹤0.01% | 2368 |
|
|
2021
Q2 | $1.58M | Buy |
5,167
+110
| +2% | +$24.1K | ﹤0.01% | 2857 |
|
|
2021
Q1 | $1.04M | Sell |
5,057
-69
| -1% | -$15.1K | ﹤0.01% | 2954 |
|
|
2020
Q4 | $1.02M | Buy |
5,126
+98
| +2% | +$20.4K | ﹤0.01% | 3519 |
|
|
2020
Q3 | $833K | Sell |
5,028
-57
| -1% | -$13K | ﹤0.01% | 3442 |
|
|
2020
Q2 | $1.26M | Sell |
5,085
-95
| -2% | -$22.2K | ﹤0.01% | 3306 |
|
|
2020
Q1 | $945K | Buy |
5,180
+5,055
| +4,044% | +$1.27M | ﹤0.01% | 3233 |
|
|
2019
Q4 | $36K | Buy |
125
+37
| +42% | +$10.3K | ﹤0.01% | 6595 |
|
|
2019
Q3 | $24K | Sell |
88
-74
| -46% | -$28.6K | ﹤0.01% | 6632 |
|
|
2019
Q2 | $61K | Sell |
162
-14
| -8% | -$4.18K | ﹤0.01% | 6292 |
|
|
2019
Q1 | $47K | Buy |
176
+6
| +4% | +$1.43K | ﹤0.01% | 6397 |
|
|
2018
Q4 | $37K | Sell |
170
-8
| -4% | -$2.48K | ﹤0.01% | 6480 |
|
|
2018
Q3 | $80K | Buy |
178
+85
| +91% | +$36.9K | ﹤0.01% | 6113 |
|
|
2018
Q2 | $38K | Buy |
93
+38
| +69% | +$18.1K | ﹤0.01% | 6496 |
|
|
2018
Q1 | $30K | Buy |
55
+51
| +1,275% | +$31.6K | ﹤0.01% | 6513 |
|
|
2017
Q4 | $2K | Buy |
4
+3
| +300% | +$1.4K | ﹤0.01% | 7409 |
|
|
2017
Q3 | $1K | Hold |
1
| – | – | ﹤0.01% | 7166 |
|
|
2017
Q2 | $0 | Buy |
+1
| New | +$292 | ﹤0.01% | 7510 |
|
|
2016
Q2 | – | Sell |
-2
| Closed | – | – | 7492 |
|
|
2016
Q1 | $0 | Buy |
+2
| New | +$281 | ﹤0.01% | 7814 |
|
Other funds holding PVLA
SCM
FLAM
BI
FLSM
VCM
Citigroup's PVLA Position: Q1 2026 in Review
Citigroup increased its Palvella Therapeutics (PVLA) stake by 25% in Q1 2026, buying an estimated $52.2K and bringing the position to 2,504 shares worth $312K. The position accounts for ﹤0.01% of the portfolio, ranked #3789.
Citigroup first reported a position in PVLA in Q1 2016 and has held it in 37 quarters since. The position peaked at $2.45M in Q3 2021. 180 funds tracked by Wall St. Rank hold PVLA as of Q1 2026.
- Citigroup held 2,504 shares of Palvella Therapeutics worth $312K as of Q1 2026.
- Citigroup bought 500 Palvella Therapeutics shares in Q1 2026, an estimated $52.2K.
- Palvella Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #3789 holding.
- Citigroup first reported a position in Palvella Therapeutics in Q1 2016 and has held it in 37 quarters since.
- Citigroup's Palvella Therapeutics position peaked at $2.45M in Q3 2021.
- 180 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q1 2026.
Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.